drugset / Trial / NCT02636686
Extension Study of Drisapersen in DMD Subjects
Summary
This is a phase IIIb, multi-centre, open-label extension study in male subjects with DMD who previously have been treated with drisapersen, aiming at assessing the safety and efficacy of drisapersen.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Drisapersen | Antisense oligonucleotide | 3 mg/kg | Subcutaneous |
| Subject | Drisapersen | Antisense oligonucleotide | 6 mg/kg | Subcutaneous |